BioXcel Therapeutics Inc (OQ:BTAI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 555 Long Wharf Dr
NEW HAVEN CT 06511-6107
Tel: 1-475-3558462
IR: See website
Key People
Vimal Mehta
President, Chief Executive Officer, Director
Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Frank D. Yocca
Executive Vice President, Chief Scientific Officer
Vincent J. O'Neill
Executive Vice President, Chief of Product Development and Medical Officer
Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Matthew T. Wiley
Senior Vice President, Chief Commercial Officer
Business Overview
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company's most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Financial Overview
For the three months ended 31 March 2024, BioXcel Therapeutics Inc revenues increased from $206K to $582K. Net loss decreased 49% to $26.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 69% to $6.5M (expense), Personnel and related costs decrease of 66% to $3.2M (expense).
Employees: 74 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $72.53M as of Mar 31, 2024
Annual revenue (TTM): $1.76M as of Mar 31, 2024
EBITDA (TTM): -$140.27M as of Mar 31, 2024
Net annual income (TTM): -$153.05M as of Mar 31, 2024
Free cash flow (TTM): -$120.38M as of Mar 31, 2024
Net Debt Last Fiscal Year: $27.49M as of Mar 31, 2024
Shares outstanding: 37,530,821 as of May 7, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.